# US 2023/0235092 A1 · Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0235092 A1
- Document ID: US20230235092A1
- Status: Published application
- Kind: A1
- Application number: 17/936,044
- Filed: 2022-09-28
- Published: 2023-07-27
- Earliest claimed: 2021-09-29
- Assignees: ModeX Therapeutics, Inc.
- Applicants: ModeX Therapeutics
- Inventors: Ronnie Rong WEI; Ling XU; Zhi-Yong YANG; Edward SEUNG; Gary J. NABEL; Lan WU; Mark GRECI; Hao CHEN
- Web page: https://patentgrep.com/patent/US20230235092A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 16/087: Herpes simplex virus
- C07K 16/106: Picornaviridae (F), e.g. hepatitis A virus
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- C07K 16/125: {from Chlamydiales (O)}
- C07K 16/1253: {from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]}
- C07K 16/1275: Streptococcus (G)
- C07K 16/1285: {from Corynebacterium (G)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/3076: {against structure-related tumour-associated moieties}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0636: {T lymphocytes}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/62: comprising only variable region components
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/41: containing a Myc-tag
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/50: containing protease site
- C12N 2502/30: tumour cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; chimeric antigen receptors (CARs), cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

## Claims

### Claim at position 1

1-107. (canceled)

### Claim 108

An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide;
wherein the first polypeptide has a structure represented by:
VL1-VL2-VH2-VH1-Fc;
VH1-VH2-VL2-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-Fc;
VH1-L1-VH2-L2-VL2-L3-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or
VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;
wherein the second polypeptide has a structure represented by:
VL3-VH3-Fc;
VH3-VL3-Fc;
VL3-L5-VH3-Fc; or
VH3-L5-VL3-Fc; and
wherein:
VL1 is a first immunoglobulin light chain variable region;
VL2 is a second immunoglobulin light chain variable region;
VL3 is a third immunoglobulin light chain variable region;
VH1 is a first immunoglobulin heavy chain variable region;
VH2 is a second immunoglobulin heavy chain variable region;
VH3 is a third immunoglobulin heavy chain variable region;
Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge; and
L1, L2, L3, L4 and L5 are amino acid linkers.

### Claim 109 (depends on 108)

The antigen binding polypeptide complex of claim 108,
wherein the first polypeptide has a structure represented by:
VL1-VL2-VH2-VH1-CH1-Fc;
VH1-VH2-VL2-VL1-CH1-Fc;
VL1-VL2-VH2-VH1-CL-Fc;
VH1-VH2-VL2-VL1-CL-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;
VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; or
VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;
wherein the second polypeptide has a structure represented by:
VL3-VH3-CH1-Fc;
VH3-VL3-CH1-Fc;
VL3-VH3-CL-Fc;
VH3-VL3-CL-Fc;
VL3-L5-VH3-L6-CH1-L7-Fc;
VH3-L5-VL3-L6-CH1-L7-Fc;
VL3-L5-VH3-L6-CL-L7-Fc; or
VH3-L5-VL3-L6-CL-L7-Fc; and
wherein:
CH1 is an immunoglobulin heavy chain constant region 1;
CL is an immunoglobulin light chain constant region; and
L1, L2, L3, L4, L5, L6, and L7 are amino acid linkers.

### Claim 110 (depends on 108)

The antigen binding polypeptide complex of claim 108,
wherein the second polypeptide has a structure represented by:
VL3-VH3-CH1-CL-Fc;
VH3-VL3-CH1-CL-Fc;
VL3-VH3-CL-CH1-Fc;
VH3-VL3-CL-CH1-Fc;
VL3-L6-VH3-L7-CH1-L8-CL-Fc;
VH3-L6-VL3-L7-CH1-L8-CL-Fc;
VL3-L6-VH3-L7-CL-L8-CH1-Fc;
VH3-L6-VL3-L7-CL-L8-CH1-Fc;
VL3-VH3-L6-CH1-CL-Fc;
VH3-VL3-L6-CH1-CL-Fc;
VL3-VH3-L6-CL-CH1-Fc; or
VH3-VL3-L6-CL-CH1-Fc; and
wherein:
CH1 is an immunoglobulin heavy chain constant region 1;
CL is an immunoglobulin light chain constant region; and
L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.

### Claim 111 (depends on 108)

The antigen binding polypeptide complex of claim 108,
wherein the second polypeptide has a structure represented by:
VL3-CL-VH3-CH1-Fc;
VL3-CH1-VH3-CL-Fc;
VH3-CH1-VL3-CL-Fc;
VH3-CL-VL3-CH1-Fc;
VL3-L6-CL-L7-VH3-L8-CH1-Fc;
VL3-L6-CH1-L7-VH3-L8-CL-Fc;
VH3-L6-CH1-L7-VL3-L8-CL-Fc;
VH3-L6-CL-L7-VL3-L8-CH1-Fc;
VL3-CL-L6-VH3-CH1-Fc;
VL3-CH1-L6-VH3-CL-Fc;
VH3-CH1-L6-VL3-CL-Fc; or
VH3-CL-L6-VL3-CH1-Fc; and
wherein:
CH1 is an immunoglobulin heavy chain constant region 1;
CL is an immunoglobulin light chain constant region; and
L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.

### Claim 112

An antigen binding polypeptide complex comprising a first polypeptide, a second polypeptide, and a third polypeptide;
wherein the first polypeptide has a structure represented by:
VL1-VL2-VH2-VH1-Fc;
VH1-VH2-VL2-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-Fc;
VH1-L1-VH2-L2-VL2-L3-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or
VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;
wherein the second polypeptide has a structure represented by:
VL3; or
VL3-L5;
wherein the third polypeptide has a structure represented by:
VH3-Fc; or
VH3-L6-Fc; and
wherein:
VL1 is a first immunoglobulin light chain variable region;
VL2 is a second immunoglobulin light chain variable region;
VL3 is a third immunoglobulin light chain variable region;
VH1 is a first immunoglobulin heavy chain variable region;
VH2 is a second immunoglobulin heavy chain variable region;
VH3 is a third immunoglobulin heavy chain variable region;
Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge; and
L1, L2, L3, L4, L5 and L6 are amino acid linkers.

### Claim 113 (depends on 112)

The antigen binding polypeptide complex of claim 112,
wherein the second polypeptide has a structure represented by:
VL3-CH1;
VL3-CL;
VL3-L5-CH1; or
VL3-L5-CL;
wherein the third polypeptide has a structure represented by:
VH3-CH1-Fc;
VH3-CL-Fc;
VH3-L6-Fc;
VH3-L6-CH1-Fc; or
VH3-L6-CL-Fc; and
wherein:
CH1 is an immunoglobulin heavy chain constant region 1; and
CL is an immunoglobulin light chain constant region.

### Claim 114

An antigen binding polypeptide complex comprising a first polypeptide, a second polypeptide, and a third polypeptide;
wherein the first polypeptide has a structure represented by:
VL1-VL2-VH2-VH1-Fc;
VH1-VH2-VL2-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-Fc;
VH1-L1-VH2-L2-VL2-L3-VL1-Fc;
VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or
VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;
wherein the second polypeptide has a structure represented by:
VL3-Fc; or
VL3-L5-Fc;
wherein the third polypeptide has a structure represented by:
VH3; or
VH3-L6; and
wherein:
VL1 is a first immunoglobulin light chain variable region;
VL2 is a second immunoglobulin light chain variable region;
VL3 is a third immunoglobulin light chain variable region;
VH1 is a first immunoglobulin heavy chain variable region;
VH2 is a second immunoglobulin heavy chain variable region;
VH3 is a third immunoglobulin heavy chain variable region;
Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge; and
L1, L2, L3, L4, L5 and L6 are amino acid linkers.

### Claim 115 (depends on 114)

The antigen binding polypeptide complex of claim 114,
wherein the second polypeptide has a structure represented by:
VL3-CH1-Fc;
VL3-CL-Fc;
VL3-L5-CH1-Fc; or
VL3-L5-CL-Fc;
wherein the third polypeptide has a structure represented by:
VH3-CH1;
VH3-CL;
VH3-L6-CH1; or
VH3-L6-CL; and
wherein:
CH1 is an immunoglobulin heavy chain constant region 1; and
CL is an immunoglobulin light chain constant region.

### Claim 116 (depends on 108)

The antigen binding polypeptide complex of claim 108, wherein VH1, VH2 and VH3 each bind to different antigens, and VL1, VL2 and VL3 each bind to different antigens.

### Claim 117 (depends on 108)

The antigen binding polypeptide complex of claim 108, wherein linkers L1, L2, L3, L4 and L5 each comprise an amino acid sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 665-672.

### Claim 118 (depends on 112)

The antigen binding polypeptide complex of claim 112, wherein linkers L1, L2, L3, L4, L5 and L6 each comprise an amino acid sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 665-672.

### Claim 119 (depends on 114)

The antigen binding polypeptide complex of claim 114, wherein linkers L1, L2, L3, L4, L5 and L6 each comprise an amino acid sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 665-672.

### Claim 120 (depends on 108)

The antigen binding polypeptide complex of claim 108, wherein the Fc region comprises at least one knob-into-hole modification.

### Claim 121 (depends on 112)

The antigen binding polypeptide complex of claim 112, wherein the Fc region comprises at least one knob-into-hole modification.

### Claim 122 (depends on 114)

The antigen binding polypeptide complex of claim 114, wherein the Fc region comprises at least one knob-into-hole modification.

### Claim 123 (depends on 108)

An antibody or antigen binding fragment thereof comprising the antigen binding polypeptide complex of claim 108.

### Claim 124 (depends on 123)

The antibody or antigen binding fragment thereof of claim 123, wherein the antigen binding fragment is a Fab, scFab, Fab′, F(ab′)2, Fv, or scFv.

### Claim 125

A polypeptide having at least 95% identity to any one of SEQ ID NOs:78-92.

### Claim 126

A polynucleotide having at least 95% identity to any one of SEQ ID NOs:93-107.

### Claim 127 (depends on 108)

A pharmaceutical composition comprising the antigen binding polypeptide complex of claim 108, and (ii) a pharmaceutically acceptable carrier.

### Claim 128 (depends on 108)

A pharmaceutical composition comprising (i) a polynucleotide encoding the antigen binding polypeptide complex of claim 108, and (ii) a pharmaceutically acceptable carrier.

### Claim 129 (depends on 108)

A method of treating or preventing a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the antigen binding polypeptide complex of claim 108.

### Claim 130 (depends on 108)

A method of treating or preventing a virus infection, comprising administering to a subject in need thereof a therapeutically effective amount of the antigen binding polypeptide complex of claim 108.
